Bulk Price Fmoc-Nalpha-Methyl-L-Valine Quote 2026
- 2026 Market Outlook: Anticipated stability in raw material costs allows for locked-in long-term contracts for peptide building blocks.
- Technical Specifications: Guaranteed industrial purity exceeding 98.5% with comprehensive COA documentation for every batch.
- Volume Scaling: Tiered pricing structures available for kilogram to metric ton procurement to optimize R&D and production budgets.
The demand for non-canonical amino acids in solid-phase peptide synthesis (SPPS) continues to accelerate as pharmaceutical developers seek to enhance metabolic stability and bioavailability in therapeutic candidates. Among these critical building blocks, Fmoc-Nalpha-Methyl-L-Valine (CAS: 84000-11-3) stands out as a essential reagent for introducing steric hindrance and preventing racemization during coupling steps. As we approach 2026, procurement strategies must evolve to account for supply chain resilience and consistent quality assurance. This technical overview provides a detailed analysis of pricing tiers, synthesis standards, and volume discount structures available for industrial buyers.
Technical Specifications and Quality Standards
Ensuring consistent quality in peptide synthesis requires rigorous adherence to specification limits. Variations in optical rotation or impurity profiles can significantly impact downstream coupling yields. Our production facilities maintain strict control over the manufacturing process to ensure that every batch meets the high standards required for GMP-adjacent environments. Below are the standard technical parameters expected for commercial-grade procurement.
| Parameter | Specification | Test Method |
|---|---|---|
| CAS Number | 84000-11-3 | N/A |
| Molecular Formula | C21H23NO4 | Elemental Analysis |
| Molecular Weight | 353.4 g/mol | Mass Spectrometry |
| Purity (HPLC) | > 98.5% | Area Normalization |
| Optical Rotation | -15° to -19° (c=1 in DMF) | Polarimetry |
| Appearance | White to Off-White Powder | Visual Inspection |
| Storage Conditions | 2-8°C, Protected from Light | Stability Study |
Buyers should note that solubility profiles are critical for automated synthesizers. This compound typically shows faint turbidity in methanol but dissolves readily in DMF or DCM with base activation. Documentation such as the COA (Certificate of Analysis) is provided with every shipment to verify these parameters against internal quality control benchmarks.
Synthesis Route and Industrial Purity
The production of Fmoc-N-Me-Val-OH involves the selective N-methylation of L-valine followed by protection with 9-fluorenylmethoxycarbonyl chloride. Achieving high industrial purity requires careful control of reaction conditions to minimize di-methylation byproducts and unreacted starting materials. Advanced crystallization techniques are employed to remove residual solvents and inorganic salts, ensuring the final product is suitable for sensitive coupling reactions.
As a global manufacturer, NINGBO INNO PHARMCHEM CO.,LTD. utilizes scalable synthesis routes that maintain yield consistency across batch sizes ranging from laboratory grams to industrial metric tons. This scalability is vital for clients transitioning from lead optimization to clinical trial material production. The chemical identity, often referenced systematically as N-[(9H-Fluoren-9-ylmethoxy)carbonyl]-N-methylvaline, must remain stable during storage to prevent decarboxylation or Fmoc group migration.
Bulk Pricing Tiers for 2026
Market analysis for 2026 indicates a stabilization of raw material costs for fluorenyl derivatives, allowing for more predictable budgeting for peptide chemists. However, bulk price fluctuations can still occur based on energy costs and logistics. To mitigate this, we offer structured pricing tiers that reward volume commitment.
Volume Discount Structures
Procurement costs are inversely related to order volume. Small-scale R&D purchases incur higher per-gram costs due to packaging and quality control overhead. Conversely, large-scale production orders benefit from streamlined logistics and bulk reactor utilization. The following table outlines the projected discount structures for the upcoming fiscal year.
| Order Volume | Price Tier | Lead Time | Documentation |
|---|---|---|---|
| 10g - 100g | Standard List Price | 3-5 Business Days | Standard COA |
| 100g - 1kg | 5% Discount | 5-7 Business Days | Full Analytical Report |
| 1kg - 10kg | 12% Discount | 7-10 Business Days | Batch Specific Data |
| 10kg + | Custom Quote (15%+) | Negotiated | Validation Support |
These tiers are designed to support both academic research groups and commercial pharmaceutical entities. For orders exceeding 10kg, clients can negotiate long-term supply agreements that lock in pricing against market volatility, ensuring budget certainty for multi-year projects.
Request Custom Quote and Procurement
Securing the best value requires direct engagement with the manufacturing source rather than relying on secondary distributors. When sourcing high-purity Fmoc-Nalpha-methyl-L-valine, buyers should prioritize suppliers who can provide immediate technical support and custom synthesis capabilities. Our team is equipped to handle specific packaging requirements, such as nitrogen-flushed containers to prevent moisture degradation during transit.
To initiate a procurement request, clients should submit their required volume and desired delivery timeline. Our sales engineers will generate a formal quotation including freight estimates and estimated arrival dates. For complex projects requiring custom purity profiles or specific isotopic labeling, our R&D department can collaborate on bespoke synthesis routes.
Supply Chain Reliability
In the current geopolitical climate, supply chain redundancy is crucial. NINGBO INNO PHARMCHEM CO.,LTD. maintains robust inventory levels of key intermediates to prevent stockouts. We understand that delays in building block delivery can halt entire peptide synthesis campaigns. Therefore, we prioritize expedited shipping options for urgent orders and maintain safety stock for high-demand items.
By partnering directly with a primary manufacturer, clients gain transparency into the production lifecycle. This includes access to batch records, stability data, and regulatory support files necessary for drug master files (DMF). As the industry moves towards 2026, the ability to secure reliable, high-quality inputs will be a key differentiator in successful drug development.
Conclusion
The procurement of Fmoc-Nalpha-Methyl-L-Valine for 2026 should be viewed as a strategic investment in product quality and timeline adherence. With competitive bulk pricing, verified industrial purity, and a commitment to technical excellence, we provide the foundation for successful peptide therapeutics development. Contact our sales team today to discuss your volume requirements and secure your supply chain for the coming year.